LLY ELI LILLY & Co
Pharmaceutical Preparations · NYSE · SEC CIK 59478 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY45.5%
TTM net income YoY49.8%
TTM EPS YoY50.7%
Revenue 3-yr CAGR39.2%
Net income 3-yr CAGR76.8%
Margins
Gross margin83.6%
Operating margin—
Net margin31.9%
FCF margin—
EBITDA margin—
Returns
ROE86.1%
ROA21.0%
ROIC (approx.)—
Asset turnover0.66x
Leverage & solvency
Liabilities / assets72.8%
Debt / equity1.23x
Current ratio1.39x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.11x
Accruals ratio-2.3%
Payout ratio21.7%
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $24.40B | $22.97B | $19.80B | $19.29B | $17.60B | $15.56B | $12.73B | $13.53B |
| Cost of revenue | $3.93B | $3.27B | $3.58B | $3.37B | $3.01B | $2.45B | $2.23B | $2.40B |
| Gross profit | $20.46B | $19.71B | $16.22B | $15.92B | $14.59B | $13.11B | $10.50B | $11.13B |
| R&D expense | $4.25B | $3.82B | $3.51B | $3.80B | $3.47B | $3.34B | $2.73B | $3.02B |
| SG&A expense | $3.12B | $3.43B | $2.93B | $3.13B | $2.74B | $2.75B | $2.47B | $2.42B |
| Interest expense | — | — | — | $222.60M | $179.60M | $249.00M | $243.70M | $224.70M |
| Pretax income | $8.41B | $9.25B | $8.85B | $8.27B | $7.23B | $6.78B | $3.46B | $5.04B |
| Income tax | $1.96B | $2.15B | $1.45B | $1.63B | $1.65B | $1.12B | $697.00M | $628.90M |
| Net income | $6.45B | $7.09B | $7.40B | $6.64B | $5.58B | $5.66B | $2.76B | $4.41B |
| EPS (basic) | 7.23 | 7.95 | 8.27 | — | 6.22 | 6.30 | 3.07 | — |
| EPS (diluted) | 7.22 | 7.94 | 8.26 | — | 6.21 | 6.29 | 3.06 | — |
| Dividends declared per share | 0.00 | 3.46 | — | 3.23 | 0.00 | 3.00 | — | 2.80 |
| Weighted avg. shares (diluted) | 893.40M | 893.70M | 895.90M | — | 898.80M | 899.80M | 900.60M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.88B | $8.95B | $5.28B | $7.27B | $9.79B | $3.38B | $3.09B | $3.27B |
| Short-term investments | — | — | — | — | $121.60M | $170.10M | $127.40M | $154.80M |
| Receivables | $22.09B | $20.08B | $18.43B | $17.76B | $16.11B | $14.17B | $12.04B | $11.01B |
| Inventory | $18.19B | $16.79B | $14.53B | $13.74B | $12.18B | $11.01B | $9.31B | $7.59B |
| Current assets | $65.26B | $64.67B | $54.84B | $55.63B | $62.07B | $49.85B | $41.26B | $32.74B |
| PP&E, net | $32.19B | $29.29B | $26.54B | $24.68B | $22.32B | $20.53B | $18.47B | $17.10B |
| Goodwill | $9.87B | $8.85B | $6.13B | $5.90B | $5.90B | $5.77B | $5.77B | $5.77B |
| Intangibles | $18.08B | $18.11B | $7.37B | $6.52B | $6.45B | $5.91B | $6.01B | $6.17B |
| Total assets | $148.07B | $142.28B | $116.58B | $112.48B | $114.94B | $100.92B | $89.39B | $78.72B |
| Current liabilities | $47.00B | $47.74B | $36.63B | $35.23B | $40.14B | $39.02B | $30.07B | $28.38B |
| Short-term debt | $2.52B | $7.05B | $4.00B | $1.64B | $1.63B | $5.72B | $4.02B | $5.12B |
| Long-term debt | $46.99B | $47.86B | $39.37B | $40.87B | $40.87B | $34.18B | $34.50B | $28.53B |
| Total debt | $49.50B | $54.91B | $43.37B | $42.50B | $42.51B | $39.90B | $38.52B | $33.64B |
| Total liabilities | $107.80B | $108.40B | $85.38B | $85.94B | $91.08B | $82.57B | $73.54B | $64.44B |
| Shareholders' equity | $40.27B | $33.88B | $31.20B | $26.54B | $23.79B | $18.27B | $15.76B | $14.27B |
| Net debt | $44.62B | $45.96B | $38.09B | $35.23B | $32.71B | $36.53B | $35.42B | $30.38B |
| Cash flow statement | ||||||||
| Operating cash flow | $11.40B | $10.69B | $5.33B | $3.22B | $8.84B | $3.09B | $1.67B | $2.47B |
| Investing cash flow | -$8.30B | -$15.40B | -$3.92B | -$2.80B | -$2.98B | -$1.83B | -$3.35B | -$1.92B |
| Financing cash flow | -$7.22B | $8.43B | -$3.47B | -$2.88B | $531.00M | -$1.25B | $1.38B | -$225.40M |
| Depreciation & amortization | $545.00M | $534.00M | $509.00M | $586.00M | $470.00M | $478.00M | $463.00M | $484.80M |
| Stock-based compensation | $200.00M | $201.00M | $161.00M | $136.10M | $151.00M | $185.00M | $154.00M | $141.90M |
| Dividends paid | $1.54B | $1.55B | $1.55B | $1.35B | $1.35B | $1.35B | $1.35B | $1.17B |
| Share buybacks | $377.00M | $1.60B | $2.36B | $1.51B | $708.00M | $692.20M | $1.20B | $2.05B |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.